All of the tested HSP90 inhibitors to date have been N‐terminal inhibitors; 17‐AAG, 17‐DMAG, AUY922, ganetespib, and IPI‐504 have been evaluated as mono‐ or combination therapy in triple‐negative and HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.